Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Evaluation of a Novel Slow-Release Paclitaxel-Eluting Stent With a Bioabsorbable Polymeric Surface Coating
JACC: Cardiovascular Interventions, Volume 1, No. 1, Year 2008
Notification
URL copied to clipboard!
Description
Objectives: We sought to evaluate a new second-generation drug-eluting stent (DES), comprising a slow-release biodegradable polylactide coglycolide (PLGA) polymer and low-dose paclitaxel on a thin-strut cobalt chromium stent platform, in a clinically relevant animal model. Background: Our previous work demonstrated subacute vascular toxicity and necrosis triggering late excess neointima in pig coronaries, with a moderate paclitaxel dose eluted from an erodible polymer. The use of slower-releasing absorbable polymers with lower doses of paclitaxel is expected to minimize such adverse outcomes. Methods: Three types of stents were implanted in pig coronary arteries using quantitative coronary angiography to optimize stent apposition: bare-metal stents (BMS); absorbable, slow-release polymer-coated-only stents (POLY); and absorbable polymer-based paclitaxel-eluting stents (PACL). The dose density of paclitaxel was 0.15 μg/mm2 with in vitro studies demonstrating a gradual elution over the course of 12 to 16 weeks. Animals underwent angiographic restudy and were terminated at 1 and 3 months for complete histopathologic and histomorphometric analyses. Results: At 1 month, intimal thickness varied significantly according to stent type, with the lowest level for the PACL group compared with the BMS and POLY groups (0.06 ± 0.02 mm vs. 0.17 ± 0.07 mm, 0.17 ± 0.08 mm, respectively, p < 0.001); histological percent area stenosis was 18 ± 4% for PACL compared with 27 ± 7% for BMS and 30 ± 12% for POLY, respectively (p = 0.001). At 3 months, PACL showed similar neointimal thickness as BMS and POLY (0.09 ± 0.05 mm vs. 0.13 ± 0.10 mm and 0.11 ± 0.03 mm respectively, p = 0.582). Histological percent area stenosis was 23 ± 8% for PACL versus 23 ± 11% for BMS and 23 ± 2% for POLY, respectively (p = 1.000). Conclusions: This study shows favorable vascular compatibility and efficacy for a novel DES that elutes paclitaxel in porcine coronary arteries. These results support the notion that slowing the release rate and lowering the dose of paclitaxel favorably influences the vascular biological response to DES implant, decreasing early toxicity and promoting stable healing while still suppressing neointima formation. © 2008 American College of Cardiology Foundation.
Authors & Co-Authors
Jabara, Refat
United States, Atlanta
St. Joseph's Hospital Atlanta
Chronos, Nicolas A.F.
United States, Atlanta
St. Joseph's Hospital Atlanta
Conway, Damian
South Africa, Cape Town
Disa Vascular (pty) Ltd
Molema, Warner
South Africa, Cape Town
Disa Vascular (pty) Ltd
Robinson, Keith
United States, Atlanta
St. Joseph's Hospital Atlanta
Statistics
Citations: 25
Authors: 5
Affiliations: 2
Identifiers
Doi:
10.1016/j.jcin.2007.11.009
ISSN:
19368798
Study Approach
Quantitative